Neuromics

Executive Summary

Neuromics is a private, US-based company founded in 1998 that supplies validated reagents (antibodies, assays, probes) primarily for neuroscience research, with applications in drug discovery, toxicology, and regenerative medicine. The company serves a broad customer base including pharmaceutical companies, biotech firms, and academic laboratories. With a focus on reproducibility and trust, Neuromics offers a comprehensive catalog covering areas such as cell biology, cancer, immunology, and gene silencing. While the company operates in a competitive landscape of reagent providers, its long-standing presence and specialized neuroscience focus provide a differentiated position. However, limited public information on financials, employee count, or recent funding suggests a small-to-mid-sized enterprise with stable but modest growth. The company's ability to innovate and expand into emerging research areas (e.g., CRISPR, 3D cell models) will be key to sustaining relevance.

Upcoming Catalysts (preview)

• Q4 2026Launch of custom CRISPR/Cas9 reagent service40% success
• Q2 2027Strategic partnership with a major pharma for neuroscience assay kits30% success
• Q1 2027Expansion of 3D cell culture assay portfolio50% success